<p>Percentage of serum samples neutralizing indicated number of A9 (top panel) or A7 (bottom panel) non-vaccine types within each of the low (T1), middle (T2) or high (T3) vaccine-type tertiles (dark to light gradient shading) for indicated vaccine (blue, Cervarix®; red, Gardasil®).</p
Background and Aims: Development of a prophylactic hepatitis C virus (HCV) vaccine will require a...
Human papillomavirus (HPV) vaccines confer protection against the oncogenic genotypes HPV16 and HPV1...
<p>Vaccine-derived antibody concentrations (LU/ml) pre- (dark grey dots) and post-inhibition (light ...
<p>Box (median and IQR) and whisker (10<sup>th</sup> - 90<sup>th</sup> percentiles) plots of the mag...
<p>Percentage of vaccinees with neutralization titers of ≥20 (left panels) and GMT (right panels) ag...
<p>Antibody avidity (%) for HPV16 (A) and HPV18 (B) of HPV-specific single-seropositive and multi-se...
<p>(A) Neutralization titers were normalized to IgG levels in serum and genital samples for HPV16 (l...
a<p>Cervarix n = 91; Gardasil n = 97. <i>p</i> values <0.05 highlighted in bold type. N/A, not appli...
In order to assess HPV-specific IgG characteristics, we evaluated multiple aspects of the humoral an...
<p><u>Key</u>: HPV types showing significant differences (by Fisher's exact test p<0.1) are indicate...
We assessed HPV 16 and 18 antibody responses of female subjects enrolled in a 2- vs. 3-dose quadriva...
<p><u>Key</u>: HPV types showing significant differences (by Fisher's exact test p<0.1) are indicate...
<p><sup><i>a</i></sup> Median (inter-quartile range, IQR) for immune measures against vaccine (HPV16...
Human Papillomavirus (HPV) bivalent (Cervarix®) and quadrivalent (Gardasil®) vaccines demonstrate ro...
AbstractThe majority of cervical cancers are associated with infection by one or more Human Papillom...
Background and Aims: Development of a prophylactic hepatitis C virus (HCV) vaccine will require a...
Human papillomavirus (HPV) vaccines confer protection against the oncogenic genotypes HPV16 and HPV1...
<p>Vaccine-derived antibody concentrations (LU/ml) pre- (dark grey dots) and post-inhibition (light ...
<p>Box (median and IQR) and whisker (10<sup>th</sup> - 90<sup>th</sup> percentiles) plots of the mag...
<p>Percentage of vaccinees with neutralization titers of ≥20 (left panels) and GMT (right panels) ag...
<p>Antibody avidity (%) for HPV16 (A) and HPV18 (B) of HPV-specific single-seropositive and multi-se...
<p>(A) Neutralization titers were normalized to IgG levels in serum and genital samples for HPV16 (l...
a<p>Cervarix n = 91; Gardasil n = 97. <i>p</i> values <0.05 highlighted in bold type. N/A, not appli...
In order to assess HPV-specific IgG characteristics, we evaluated multiple aspects of the humoral an...
<p><u>Key</u>: HPV types showing significant differences (by Fisher's exact test p<0.1) are indicate...
We assessed HPV 16 and 18 antibody responses of female subjects enrolled in a 2- vs. 3-dose quadriva...
<p><u>Key</u>: HPV types showing significant differences (by Fisher's exact test p<0.1) are indicate...
<p><sup><i>a</i></sup> Median (inter-quartile range, IQR) for immune measures against vaccine (HPV16...
Human Papillomavirus (HPV) bivalent (Cervarix®) and quadrivalent (Gardasil®) vaccines demonstrate ro...
AbstractThe majority of cervical cancers are associated with infection by one or more Human Papillom...
Background and Aims: Development of a prophylactic hepatitis C virus (HCV) vaccine will require a...
Human papillomavirus (HPV) vaccines confer protection against the oncogenic genotypes HPV16 and HPV1...
<p>Vaccine-derived antibody concentrations (LU/ml) pre- (dark grey dots) and post-inhibition (light ...